According to Fior Markets latest report, the global PDX models market would register a CAGR of 17.51% during the assessment period from 2018-2025. The market is anticipated to jump from USD 79.5 million in 2017 to USD 290.14 million by 2025. North America market is expected to attain the highest growth rate over the next decade. This growth is witnessed in the wake of increasing preclinical activities by CROs and pharmaceutical companies and growing stem cell research in the region.

Global PDX Models Market by Type, Tumor Type (Mice Models and Rat Models), Application (Preclinical Drug Development, Basic Cancer Research, Biomarker Analysis), End User (Pharmaceutical & Biotechnology Companies), and Region” and Global Forecast 2018-2025.


Key players operating in the industry include The Jackson Laboratory, Crown Bioscience Inc, Champions Oncology, Inc., WuXi AppTec, ONCODESIGN, EPO Berlin-Buch GmBH, Charles River Laboratories International, Inc., Shanghai LIDE Biotech Co., Ltd, Horizon Discovery Group PLC, Xentech, Explora BioLabs, Urolead, EUROPDX, MI Bioresearch Inc, Aragen Bioscience among others. Countries under development and progressing towards growth direction including U.S, Germany, U.K, China and Japan are offering greater opportunities. For example, Crown Biosciences launched its advanced digital platform for their oncology database OncoExpress. EVOTEC has teamed up with Inserm and various other research organizations across Europe.

Based on the type segment, the market is classified into mice models and rat models. The rat models segment is projected to grow with the highest CAGR of 19.2% in the anticipated period. Main growth drivers include the development of immune-deficient rats and smaller size of rats, which will drive the usage of rat models in PDX model generation. These factors are highly contributing to the growth of the segment. Tumour type segment contains gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models and other tumor models. In 2017, gastrointestinal tumor models segment registered the largest share of 33.61%. The major contributor is increasing the focus of market players on generating lung cancer PDX models, as lung cancer is the leading cause of cancer-related deaths across the globe. The application segment includes segments such as preclinical drug development and basic cancer research and biomarker analysis. End user segment is divided into pharmaceutical & biotechnology, contract research organizations and academic & research institutions.


Increasing demand for personalized medicines is driving the market. Increased efforts for cancer research from private and public institutions are highly contributing to the growth of the market. The evaluations in the report show that ethical issues regarding the usage of animals for cancer research may hamper the growth of the market. However, increasing demand for humanized PDX models is expected to boost the growth of the market in the coming years.

Customization of the Report:
This report can be customized to meet the client’s requirements. Please connect with our sales team (, who will ensure that you get a report that suits your needs.